Rezolute (NASDAQ:RZLT – Get Free Report) and 2seventy bio (NASDAQ:TSVT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Insider and Institutional Ownership
83.0% of Rezolute shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 20.8% of Rezolute shares are held by company insiders. Comparatively, 7.2% of 2seventy bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Rezolute and 2seventy bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rezolute | N/A | -60.90% | -54.58% |
| 2seventy bio | -313.51% | -67.59% | -31.71% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rezolute | N/A | N/A | -$51.79 million | ($1.14) | -3.77 |
| 2seventy bio | $100.39 million | 2.10 | -$217.57 million | ($4.35) | -0.94 |
Rezolute has higher earnings, but lower revenue than 2seventy bio. Rezolute is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Rezolute and 2seventy bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rezolute | 0 | 0 | 7 | 0 | 3.00 |
| 2seventy bio | 1 | 4 | 4 | 1 | 2.50 |
Rezolute currently has a consensus price target of $10.14, indicating a potential upside of 135.88%. 2seventy bio has a consensus price target of $11.43, indicating a potential upside of 178.75%. Given 2seventy bio’s higher possible upside, analysts plainly believe 2seventy bio is more favorable than Rezolute.
Risk & Volatility
Rezolute has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Summary
Rezolute beats 2seventy bio on 7 of the 13 factors compared between the two stocks.
About Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About 2seventy bio
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
